---
company: Covista Inc.
ticker: CVSA
form: 8-K
filed: 2026-05-07
accession: 0000730464-26-000021
source: https://www.sec.gov/Archives/edgar/data/730464/000073046426000021/
---

# Covista (CVSA) earnings release, May 7, 2026

Covista Inc. (CVSA) · Form 8-K, Item 2.02 · Filed 2026-05-07 · [SEC filing](https://www.sec.gov/Archives/edgar/data/730464/000073046426000021/)

​

Investor Contact:

Jeremy Cohen

Investor.Relations@Covista.com

+1 312-906-6600

​

Media Contact:

Maureen Bender

CovistaMedia@Covista.com

+1 313-319-4732

Covista Third Quarter Fiscal Year 2026 Results;

Raises Fiscal Year 2026 Revenue and Adjusted Earnings Per Share Guidance

Total enrollment up 6.8% YoY, with Chamberlain returning to positive total enrollment growth

Surpassed 100,000 students including record enrollment at Chamberlain and Walden

Revenue up 4.5% YoY; revenue up 8.4% YoY when adjusted for Walden one-week academic shift

Third quarter highlights

Capital allocation

Increased fiscal year 2026 guidance

​

CHICAGO – May 7, 2026 – Covista Inc. (NYSE: CVSA), the largest healthcare educator in the United States, today reported third quarter fiscal year 2026 results (ended Mar. 31, 2026). The Company continues to execute on its Growth with Purpose strategy, leading the transformation of higher education by training the next generation of healthcare professionals at an industry-leading scale.

“The country needs more nurses, physicians, and behavioral health professionals than the current system is on pace to produce. Covista is helping close that gap. This quarter shows the strength of our model: more than 100,000 students and growth across every segment, including a return to enrollment growth at Chamberlain,” said Steve Beard, Chairman and Chief Executive Officer, Covista. “We educate practitioners, and we are increasingly connecting them to the healthcare systems that need them most. We are raising guidance because execution is translating into results. The need is urgent, our role is clear, and the opportunity ahead is significant.”

Financial Highlights

Selected financial data for the three months ended Mar. 31, 2026:

​

Business Highlights

Segment Highlights

Chamberlain

​

​

Walden

​

​

Medical and Veterinary

​

​

Fiscal Year 2026 Outlook

Covista raised its revenue guidance for fiscal year 2026 from a range of $1,900 million to $1,940 million, or approximately 6% to 8.5% growth year-over-year, to a range of $1,930 million to $1,945 million, or approximately 8% to 9% growth year-over-year. Covista also raised its adjusted earnings per share guidance from a range of $7.80 to $8.00, or approximately 17% to 20% growth year-over-year, to a range of $7.95 to $8.15, or approximately 19% to 22% growth year-over-year.

​

Conference Call and Webcast Information

Covista will hold a conference call to discuss its third quarter fiscal year 2026 results today at 4:00 p.m. CT (5:00 p.m. ET).

​

The call can be accessed by dialing +1 877-407-6184 (U.S. participants) or +1 201-389-0877 (international participants) and stating “Covista earnings call” or by using conference ID:13759299. The call will be simulcast through the Covista investor relations website at: https://investors.covista.com.

​

Covista will archive a replay of the call for 30 days. To access the replay, dial +1 877-660-6853 (U.S.) or +1 201-612-7415 (international), conference ID: 13759299, or visit the Covista investor relations website.

​

About Covista

Covista (NYSE: CVSA) is America's largest healthcare educator, serving more than 100,000 students and supported by a community of 385,000 alumni across five accredited institutions. Through personalized, tech-enabled education powered by 10,000 faculty and colleagues, Covista expands access to healthcare careers and addresses the U.S. healthcare workforce shortage at scale. Covista is the parent company of American University of the Caribbean School of Medicine, Chamberlain University, Ross University School of Medicine, Ross University School of Veterinary Medicine and Walden University. For more information, visit Covista.com and follow us on

LinkedIn,

Instagram and

YouTube.

​

Cautionary Disclosure Regarding Forward-Looking Statements

Certain statements contained in this release are forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact, which includes statements regarding Covista’s future growth. Forward-looking statements generally can be identified by the use of forward-looking terminology such as “future,” “believe,” “expect,” “anticipate,” “estimate,” “plan,” “intend,” “may,” “will,” “would,” “could,” “can,” “continue,” “preliminary,” “potential,” “range,” and similar terms. These forward-looking statements are subject to risk and uncertainties that could cause actual results to differ materially from those described in the statements. Important factors that could cause actual results to differ materially from the expectations expressed or implied by our forward-looking statements are disclosed in Item 1A. “Risk Factors,” of our Annual Report on Form 10-K. You should evaluate forward-looking statements in the context of these risks and uncertainties and are cautioned to not place undue reliance on such forward-looking statements. We caution you that these factors, performance or developments we expect or anticipate or, even if substantially realized, that they will result in the consequences or affect us or our operations in the way we expect. All forward-looking statements are based on information available to use as of the date any such statements are made, and Covista assumes no obligation to publicly update or revise its forward-looking statements even if experience or future changes make it clear that any projected results expressed or implied therein will not be realized, except as required by law.

​... (truncated).

###

​

​

Covista Inc.

Consolidated Balance Sheets

(unaudited)

(in thousands)

​

​

​

​

Covista Inc.

Consolidated Statements of Income

(unaudited)

(in thousands, except per share data)

​

​

​

​

​

Covista Inc.

Consolidated Statements of Cash Flows

(unaudited)

(in thousands)

​

​

​

​

​

Covista Inc.

Segment Revenue

(unaudited)

(in thousands)

​

​

Covista Inc.

Non-GAAP Financial Measures and Reconciliations

We believe that certain non-GAAP financial measures provide investors with useful supplemental information regarding the underlying business trends and performance of Covista’s ongoing operations as seen through the eyes of management and are useful for period-over-period comparisons. We use these supplemental non-GAAP financial measures internally in our assessment of performance and budgeting process. However, these non-GAAP financial measures should not be considered as a substitute for, or superior to, measures of financial performance prepared in accordance with GAAP. The following are non-GAAP financial measures used in the subsequent GAAP to non-GAAP reconciliation tables:

Adjusted net income (most comparable GAAP measure: net income) – Measure of Covista’s net income adjusted for restructuring expense, amortization of acquired intangible assets, strategic advisory costs, loss on debt extinguishment, litigation reserve, asset impairments, debt modification costs, and loss (income) from discontinued operations.

Adjusted earnings per share (most comparable GAAP measure: diluted earnings per share) – Measure of Covista’s diluted earnings per share adjusted for restructuring expense, amortization of acquired intangible assets, strategic advisory costs, loss on debt extinguishment, litigation reserve, asset impairments, debt modification costs, and loss (income) from discontinued operations.

Adjusted operating income (most comparable GAAP measure: operating income) – Measure of Covista’s operating income adjusted for restructuring expense, amortization of acquired intangible assets, litigation reserve, asset impairments, strategic advisory costs, and debt modification costs.

Adjusted EBITDA (most comparable GAAP measure: net income) – Measure of Covista’s net income adjusted for loss (income) from discontinued operations, interest expense, other income, net, provision for income taxes, depreciation, amortization of acquired intangible assets, amortization of cloud computing implementation assets, stock-based compensation, restructuring expense, litigation reserve, asset impairments, strategic advisory costs, and debt modification costs. Provision for income taxes, interest expense, and other income, net are not recorded at the reportable segments, and therefore, the segment adjusted EBITDA reconciliations begin with adjusted operating income.

Free cash flow (most comparable GAAP measure: net cash provided by operating activities-continuing operations) – Defined as net cash provided by operating activities-continuing operations less capital expenditures.

Net debt – Defined as long-term debt less cash and cash equivalents.

Net leverage – Defined as net debt divided by adjusted EBITDA.

A description of special items in our non-GAAP financial measures described above are as follows:

Covista Inc.

Adjusted Operating Income

(unaudited)

(in thousands)

​

​

​

​

Covista Inc.

Adjusted EBITDA

(unaudited)

(in thousands)

​

​

Covista Inc.

Adjusted Earnings

(unaudited)

(in thousands, except per share data)

​

​

Note: May not sum due to rounding.

​

Covista Inc.

Free Cash Flow

(unaudited)

(in thousands)

​

​

​

​

Covista Inc.

Net Leverage

(unaudited)

(in thousands)

​

​

## Financial statements

### Income Statement (Three Months Ended — Chamberlain (in millions))

| | Three Months Ended – March 31, – 2026 | Three Months Ended – March 31, – 2025 | Three Months Ended – March 31, – % Change |
|---|---:|---:|---:|
| Revenue | 197 | 192.6 | 2.3% |
| Operating Income | 47.7 | 47.5 | 0.4% |
| Adj. Operating Income | 47.9 | 47.5 | 0.8% |
| Adj. EBITDA | 58.5 | 56.8 | 2.9% |
| Total Students (2) | 40,767 | 40,564 | 0.5% |

### Income Statement (Three Months Ended — Walden (in millions))

| | Three Months Ended – March 31, – 2026 | Three Months Ended – March 31, – 2025 | Three Months Ended – March 31, – % Change |
|---|---:|---:|---:|
| Revenue | 186.6 | 178.4 | 4.6% |
| Operating Income | 39.5 | 45.2 | -12.5% |
| Adj. Operating Income | 42.4 | 48 | -11.7% |
| Adj. EBITDA | 49.7 | 54 | -7.9% |
| Total Students (2) | 54,474 | 48,526 | 12.3% |

### Income Statement (Three Months Ended — Medical and Veterinary (in millions))

| | Three Months Ended – March 31, – 2026 | Three Months Ended – March 31, – 2025 | Three Months Ended – March 31, – % Change |
|---|---:|---:|---:|
| Revenue | 103.5 | 95 | 8.9% |
| Operating Income | 21.1 | 17.8 | 18.7% |
| Adj. Operating Income | 21.5 | 17.9 | 20.0% |
| Adj. EBITDA | 27.5 | 22.9 | 20.1% |
| Total Students (2) | 5,344 | 5,133 | 4.1% |

### Income Statement (Three Months Ended — (in thousands, except per share data))

| | Three Months Ended – March 31, – 2026 | Three Months Ended – March 31, – 2025 | Nine Months Ended – March 31, – 2026 | Nine Months Ended – March 31, – 2025 |
|---|---:|---:|---:|---:|
| Revenue | 487,030 | 466,055 | 1,452,703 | 1,331,184 |
| Operating cost and expense: | Cost of educational services | 210,719 | 199,869 | 616,911 | 572,500 |
| Operating cost and expense: | Student services and administrative expense | 184,106 | 175,167 | 542,631 | 491,141 |
| Operating cost and expense: | Restructuring expense | 863 | 510 | 5,228 | 2,926 |
| Operating cost and expense: | Total operating cost and expense | 395,688 | 375,546 | 1,164,770 | 1,066,567 |
| Operating cost and expense: | Operating income | 91,342 | 90,509 | 287,933 | 264,617 |
| Operating cost and expense: | Interest expense | -13,629 | -13,074 | -35,636 | -41,465 |
| Operating cost and expense: | Other income, net | 232 | 1,898 | 4,422 | 6,779 |
| Operating cost and expense: | Income from continuing operations before income taxes | 77,945 | 79,333 | 256,719 | 229,931 |
| Operating cost and expense: | Provision for income taxes | -19,963 | -18,539 | -61,504 | -51,716 |
| Operating cost and expense: | Income from continuing operations | 57,982 | 60,794 | 195,215 | 178,215 |
| Discontinued operations: | (Loss) income from discontinued operations before income taxes | -21,860 | 52 | -20,810 | 6,216 |
| Discontinued operations: | Benefit from (provision for) income taxes | 5,515 | -14 | 5,440 | -1,578 |
| Discontinued operations: | (Loss) income from discontinued operations | -16,345 | 38 | -15,370 | 4,638 |
| Discontinued operations: | Net income and comprehensive income | 41,637 | 60,832 | 179,845 | 182,853 |
| Basic: | Continuing operations | 1.69 | 1.64 | 5.52 | 4.76 |
| Basic: | Discontinued operations | -0.48 | 0 | -0.43 | 0.12 |
| Basic: | Total basic earnings per share | 1.21 | 1.64 | 5.08 | 4.88 |
| Diluted: | Continuing operations | 1.67 | 1.59 | 5.42 | 4.62 |
| Diluted: | Discontinued operations | -0.47 | 0 | -0.43 | 0.12 |
| Diluted: | Total diluted earnings per share | 1.2 | 1.59 | 4.99 | 4.74 |
| Weighted-average shares outstanding: | Basic shares | 34,283 | 37,140 | 35,381 | 37,434 |
| Weighted-average shares outstanding: | Diluted shares | 34,782 | 38,233 | 36,031 | 38,583 |

### Income Statement (Three Months Ended — (in thousands))

| | Three Months Ended – March 31, – 2026 | Three Months Ended – March 31, – 2025 | Three Months Ended – March 31, – Increase/(Decrease) – $$ | Three Months Ended – March 31, – Increase/(Decrease) – % | Nine Months Ended – March 31, – 2026 | Nine Months Ended – March 31, – 2025 | Nine Months Ended – March 31, – Increase/(Decrease) – $$ | Nine Months Ended – March 31, – Increase/(Decrease) – % |
|---|---:|---:|---:|---:|---:|---:|---:|---:|
| Chamberlain: | Operating income | 47,696 | 47,516 | 180 | 0.4% | 105,302 | 115,716 | -10,414 | -9.0% |
| Chamberlain: | Restructuring expense | 199 | -23 | 222 |  | 2,024 | 1,912 | 112 |  |
| Chamberlain: | Adjusted operating income | 47,895 | 47,493 | 402 | 0.8% | 107,326 | 117,628 | -10,302 | -8.8% |
| Chamberlain: | Operating margin | 24.2% | 24.7% |  |  | 18.8% | 21.4% |  |  |
| Chamberlain: | Adjusted operating margin | 24.3% | 24.7% |  |  | 19.2% | 21.7% |  |  |
| Walden: | Operating income | 39,540 | 45,194 | -5,654 | -12.5% | 168,035 | 133,929 | 34,106 | 25.5% |
| Walden: | Restructuring expense | 31 |  | 31 |  | 460 |  | 460 |  |
| Walden: | Amortization of acquired intangible assets | 2,805 | 2,805 |  |  | 8,415 | 8,415 |  |  |
| Walden: | Litigation reserve |  |  |  |  |  | -5,550 | 5,550 |  |
| Walden: | Adjusted operating income (1) | 42,376 | 47,999 | -5,623 | -11.7% | 176,910 | 136,794 | 40,116 | 29.3% |
| Walden: | Operating margin | 21.2% | 25.3% |  |  | 28.3% | 26.2% |  |  |
| Walden: | Adjusted operating margin (1) | 22.7% | 26.9% |  |  | 29.8% | 26.8% |  |  |
| Medical and Veterinary: | Operating income | 21,127 | 17,800 | 3,327 | 18.7% | 62,454 | 53,934 | 8,520 | 15.8% |
| Medical and Veterinary: | Restructuring expense | 375 | 121 | 254 |  | 855 | 236 | 619 |  |
| Medical and Veterinary: | Adjusted operating income | 21,502 | 17,921 | 3,581 | 20.0% | 63,309 | 54,170 | 9,139 | 16.9% |
| Medical and Veterinary: | Operating margin | 20.4% | 18.7% |  |  | 20.9% | 19.4% |  |  |
| Medical and Veterinary: | Adjusted operating margin | 20.8% | 18.9% |  |  | 21.2% | 19.5% |  |  |
| Home Office: | Operating loss | -17,021 | -20,001 | 2,980 | 14.9% | -47,858 | -38,962 | -8,896 | -22.8% |
| Home Office: | Restructuring expense | 258 | 412 | -154 |  | 1,889 | 778 | 1,111 |  |
| Home Office: | Asset impairments |  | 6,442 | -6,442 |  |  | 6,442 | -6,442 |  |
| Home Office: | Strategic advisory costs | 7,238 | 5,100 | 2,138 |  | 17,032 | 5,100 | 11,932 |  |
| Home Office: | Debt modification costs |  |  |  |  |  | 712 | -712 |  |
| Home Office: | Adjusted operating loss | -9,525 | -8,047 | -1,478 | -18.4% | -28,937 | -25,930 | -3,007 | -11.6% |

### Income Statement (Three Months Ended — (in thousands))

| | Three Months Ended – March 31, – 2026 | Three Months Ended – March 31, – 2025 | Three Months Ended – March 31, – Increase/(Decrease) – $$ | Three Months Ended – March 31, – Increase/(Decrease) – % | Nine Months Ended – March 31, – 2026 | Nine Months Ended – March 31, – 2025 | Nine Months Ended – March 31, – Increase/(Decrease) – $$ | Nine Months Ended – March 31, – Increase/(Decrease) – % |
|---|---:|---:|---:|---:|---:|---:|---:|---:|
| Chamberlain: | Adjusted operating income (GAAP) | 47,895 | 47,493 | 402 | 0.8% | 107,326 | 117,628 | -10,302 | -8.8% |
| Chamberlain: | Depreciation | 6,027 | 5,350 | 677 |  | 17,108 | 16,184 | 924 |  |
| Chamberlain: | Amortization of cloud computing implementation assets | 2,073 | 786 | 1,287 |  | 5,620 | 2,253 | 3,367 |  |
| Chamberlain: | Stock-based compensation | 2,465 | 3,178 | -713 |  | 8,709 | 10,290 | -1,581 |  |
| Chamberlain: | Adjusted EBITDA (non-GAAP) | 58,460 | 56,807 | 1,653 | 2.9% | 138,763 | 146,355 | -7,592 | -5.2% |
| Chamberlain: | Adjusted EBITDA margin (non-GAAP) | 29.7% | 29.5% |  |  | 24.8% | 27.0% |  |  |
| Walden: | Adjusted operating income (GAAP) | 42,376 | 47,999 | -5,623 | -11.7% | 176,910 | 136,794 | 40,116 | 29.3% |
| Walden: | Depreciation | 2,075 | 1,951 | 124 |  | 6,089 | 5,428 | 661 |  |
| Walden: | Amortization of cloud computing implementation assets | 1,918 | 763 | 1,155 |  | 5,023 | 2,242 | 2,781 |  |
| Walden: | Stock-based compensation | 3,374 | 3,288 | 86 |  | 10,264 | 9,354 | 910 |  |
| Walden: | Adjusted EBITDA (non-GAAP) (1) | 49,743 | 54,001 | -4,258 | -7.9% | 198,286 | 153,818 | 44,468 | 28.9% |
| Walden: | Adjusted EBITDA margin (non-GAAP) (1) | 26.7% | 30.3% |  |  | 33.4% | 30.1% |  |  |
| Medical and Veterinary: | Adjusted operating income (GAAP) | 21,502 | 17,921 | 3,581 | 20.0% | 63,309 | 54,170 | 9,139 | 16.9% |
| Medical and Veterinary: | Depreciation | 3,109 | 2,785 | 324 |  | 8,936 | 8,098 | 838 |  |
| Medical and Veterinary: | Amortization of cloud computing implementation assets | 720 | 304 | 416 |  | 1,836 | 902 | 934 |  |
| Medical and Veterinary: | Stock-based compensation | 2,129 | 1,848 | 281 |  | 6,221 | 5,613 | 608 |  |
| Medical and Veterinary: | Adjusted EBITDA (non-GAAP) | 27,460 | 22,858 | 4,602 | 20.1% | 80,302 | 68,783 | 11,519 | 16.7% |
| Medical and Veterinary: | Adjusted EBITDA margin (non-GAAP) | 26.5% | 24.0% |  |  | 26.9% | 24.7% |  |  |
| Home Office: | Adjusted operating loss | -9,525 | -8,047 | -1,478 | -18.4% | -28,937 | -25,930 | -3,007 | -11.6% |
| Home Office: | Depreciation | 166 | 188 | -22 |  | 494 | 557 | -63 |  |
| Home Office: | Stock-based compensation | 1,603 | 1,949 | -346 |  | 5,909 | 5,924 | -15 |  |
| Home Office: | Adjusted EBITDA | -7,756 | -5,910 | -1,846 | -31.2% | -22,534 | -19,449 | -3,085 | -15.9% |
| Covista: | Net income (GAAP) | 41,637 | 60,832 | -19,195 | -31.6% | 179,845 | 182,853 | -3,008 | -1.6% |
| Covista: | Loss (income) from discontinued operations | 16,345 | -38 | 16,383 |  | 15,370 | -4,638 | 20,008 |  |
| Covista: | Interest expense | 13,629 | 13,074 | 555 |  | 35,636 | 41,465 | -5,829 |  |
| Covista: | Other income, net | -232 | -1,898 | 1,666 |  | -4,422 | -6,779 | 2,357 |  |
| Covista: | Provision for income taxes | 19,963 | 18,539 | 1,424 |  | 61,504 | 51,716 | 9,788 |  |
| Covista: | Depreciation and amortization | 18,893 | 14,932 | 3,961 |  | 53,521 | 44,079 | 9,442 |  |
| Covista: | Stock-based compensation | 9,571 | 10,263 | -692 |  | 31,103 | 31,181 | -78 |  |
| Covista: | Restructuring expense | 863 | 510 | 353 |  | 5,228 | 2,926 | 2,302 |  |
| Covista: | Litigation reserve |  |  |  |  |  | -5,550 | 5,550 |  |
| Covista: | Asset impairments |  | 6,442 | -6,442 |  |  | 6,442 | -6,442 |  |
| Covista: | Strategic advisory costs | 7,238 | 5,100 | 2,138 |  | 17,032 | 5,100 | 11,932 |  |
| Covista: | Debt modification costs |  |  |  |  |  | 712 | -712 |  |
| Covista: | Adjusted EBITDA (non-GAAP) (1) | 127,907 | 127,756 | 151 | 0.1% | 394,817 | 349,507 | 45,310 | 13.0% |
| Covista: | Adjusted EBITDA margin (non-GAAP) (1) | 26.3% | 27.4% |  |  | 27.2% | 26.3% |  |  |

### Income Statement (Three Months Ended — (in thousands, except per share data))

| | Three Months Ended – March 31, – 2026 | Three Months Ended – March 31, – 2025 | Nine Months Ended – March 31, – 2026 | Nine Months Ended – March 31, – 2025 |
|---|---:|---:|---:|---:|
| Diluted earnings per share (GAAP) | 1.2 | 1.59 | 4.99 | 4.74 |
| Effect on diluted earnings per share: | Restructuring expense | 0.02 | 0.01 | 0.15 | 0.08 |
| Effect on diluted earnings per share: | Amortization of acquired intangible assets | 0.08 | 0.07 | 0.23 | 0.22 |
| Effect on diluted earnings per share: | Strategic advisory costs | 0.21 | 0.13 | 0.47 | 0.13 |
| Effect on diluted earnings per share: | Loss on debt extinguishment, litigation reserve, asset impairments, and debt modification costs | 0.11 | 0.21 | 0.13 | 0.09 |
| Effect on diluted earnings per share: | Income tax impact on non-GAAP adjustments (1) | -0.11 | -0.11 | -0.24 | -0.12 |
| Effect on diluted earnings per share: | Loss (income) from discontinued operations | 0.47 | 0 | 0.43 | -0.12 |
| Effect on diluted earnings per share: | Adjusted earnings per share (non-GAAP) | 1.98 | 1.92 | 6.16 | 5.01 |

### Income Statement (Twelve Months Ended — (in thousands))

| | Twelve Months Ended – March 31, 2026 | March 31, 2026 |
|---|---:|---:|
| Covista: | Net income (GAAP) | 234,057 |  |
| Covista: | Loss from discontinued operations | 15,620 |  |
| Covista: | Interest expense | 46,489 |  |
| Covista: | Other income, net | -6,933 |  |
| Covista: | Provision for income taxes | 75,625 |  |
| Covista: | Depreciation and amortization | 68,607 |  |
| Covista: | Stock-based compensation | 41,512 |  |
| Covista: | Restructuring expense | 5,616 |  |
| Covista: | Strategic advisory costs | 23,932 |  |
| Covista: | Loss on assets held for sale | 490 |  |
| Covista: | Adjusted EBITDA (non-GAAP) | 505,015 |  |
| Covista: | Long-term debt |  | 510,000 |
| Covista: | Less: Cash and cash equivalents |  | -146,977 |
| Covista: | Net debt (non-GAAP) |  | 363,023 |
| Covista: | Net leverage (non-GAAP) |  | 0.7 x |

### Balance Sheet ((in thousands))

| | March 31, – 2026 | June 30, – 2025 |
|---|---:|---:|
| Current assets: | Cash and cash equivalents | 146,977 | 199,601 |
| Current assets: | Restricted cash | 1,862 | 1,563 |
| Current assets: | Accounts and financing receivables, net | 175,924 | 146,189 |
| Current assets: | Prepaid expenses and other current assets | 78,992 | 68,837 |
| Current assets: | Total current assets | 403,755 | 416,190 |
| Noncurrent assets: | Property and equipment, net | 276,972 | 256,131 |
| Noncurrent assets: | Operating lease assets | 201,079 | 191,194 |
| Noncurrent assets: | Deferred income taxes |  | 32,956 |
| Noncurrent assets: | Intangible assets, net | 757,059 | 765,474 |
| Noncurrent assets: | Goodwill | 961,262 | 961,262 |
| Noncurrent assets: | Other assets, net | 137,300 | 129,145 |
| Noncurrent assets: | Total noncurrent assets | 2,333,672 | 2,336,162 |
| Noncurrent assets: | Total assets | 2,737,427 | 2,752,352 |
| Current liabilities: | Accounts payable | 97,261 | 105,017 |
| Current liabilities: | Accrued payroll and benefits | 75,093 | 76,374 |
| Current liabilities: | Accrued liabilities | 92,846 | 77,286 |
| Current liabilities: | Deferred revenue | 276,192 | 214,091 |
| Current liabilities: | Current operating lease liabilities | 35,230 | 35,159 |
| Current liabilities: | Current portion of long-term debt | 3,825 |  |
| Current liabilities: | Total current liabilities | 580,447 | 507,927 |
| Noncurrent liabilities: | Long-term debt | 495,644 | 552,669 |
| Noncurrent liabilities: | Long-term operating lease liabilities | 201,595 | 186,172 |
| Noncurrent liabilities: | Deferred income taxes | 58,731 | 31,856 |
| Noncurrent liabilities: | Other liabilities | 36,905 | 40,103 |
| Noncurrent liabilities: | Total noncurrent liabilities | 792,875 | 810,800 |
| Noncurrent liabilities: | Total liabilities | 1,373,322 | 1,318,727 |
| Commitments and contingencies | Total shareholders' equity | 1,364,105 | 1,433,625 |
| Commitments and contingencies | Total liabilities and shareholders' equity | 2,737,427 | 2,752,352 |

### Cash Flow (Nine Months Ended — (in thousands))

| | Nine Months Ended – March 31, – 2026 | Nine Months Ended – March 31, – 2025 |
|---|---:|---:|
| Operating activities: | Net income | 179,845 | 182,853 |
| Operating activities: | Loss (income) from discontinued operations | 15,370 | -4,638 |
| Operating activities: | Income from continuing operations | 195,215 | 178,215 |
| Adjustments to reconcile net income to net cash provided by operating activities: | Stock-based compensation | 31,103 | 31,181 |
| Adjustments to reconcile net income to net cash provided by operating activities: | Amortization and impairments to operating lease assets | 21,004 | 25,330 |
| Adjustments to reconcile net income to net cash provided by operating activities: | Depreciation | 32,627 | 30,267 |
| Adjustments to reconcile net income to net cash provided by operating activities: | Amortization of acquired intangible assets | 8,415 | 8,415 |
| Adjustments to reconcile net income to net cash provided by operating activities: | Amortization and write-off of debt discount and issuance costs | 6,961 | 4,995 |
| Adjustments to reconcile net income to net cash provided by operating activities: | Provision for bad debts | 48,853 | 46,854 |
| Adjustments to reconcile net income to net cash provided by operating activities: | Deferred income taxes | 65,318 | 19,994 |
| Adjustments to reconcile net income to net cash provided by operating activities: | Loss on disposals and impairments of property and equipment | 605 | 2,522 |
| Adjustments to reconcile net income to net cash provided by operating activities: | Gain on investments | -561 | -268 |
| Changes in assets and liabilities: | Accounts and financing receivables | -76,271 | -80,613 |
| Changes in assets and liabilities: | Prepaid expenses and other current assets | -896 | 5,727 |
| Changes in assets and liabilities: | Cloud computing implementation assets | -10,087 | -21,959 |
| Changes in assets and liabilities: | Accounts payable | -12,607 | -9,978 |
| Changes in assets and liabilities: | Accrued payroll and benefits | -1,136 | 1,406 |
| Changes in assets and liabilities: | Accrued liabilities | -10,168 | -10,449 |
| Changes in assets and liabilities: | Deferred revenue | 66,322 | 66,081 |
| Changes in assets and liabilities: | Operating lease liabilities | -15,395 | -17,839 |
| Changes in assets and liabilities: | Other assets and liabilities | -2,888 | -6,068 |
| Changes in assets and liabilities: | Net cash provided by operating activities-continuing operations | 346,414 | 273,813 |
| Changes in assets and liabilities: | Net cash provided by operating activities-discontinued operations | 45 | 4,394 |
| Changes in assets and liabilities: | Net cash provided by operating activities | 346,459 | 278,207 |
| Investing activities: | Capital expenditures | -50,882 | -31,337 |
| Investing activities: | Proceeds from sales of marketable securities | 2,314 | 3,120 |
| Investing activities: | Purchases of marketable securities | -2,313 | -2,048 |
| Investing activities: | Payment for investment in business | -5,000 |  |
| Investing activities: | Net cash used in investing activities | -55,881 | -30,265 |
| Financing activities: | Proceeds from exercise of stock options | 131 | 10,008 |

### Cash Flow (Twelve Months Ended — (in thousands))

| | Twelve Months Ended – FY25 – Q3 | Twelve Months Ended – FY25 – Q4 | Twelve Months Ended – FY26 – Q1 | Twelve Months Ended – FY26 – Q2 | Twelve Months Ended – FY26 – Q3 |
|---|---:|---:|---:|---:|---:|
| Net cash provided by operating activities-continuing operations (GAAP) | 335,069 | 333,734 | 374,796 | 427,890 | 406,335 |
| Capital expenditures | -47,914 | -50,327 | -55,936 | -59,880 | -69,872 |
| Free cash flow (non-GAAP) | 287,155 | 283,407 | 318,860 | 368,010 | 336,463 |
